Natera blood-based colorectal cancer screening for average-risk adults
Official title: Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
Run by Natera, Inc. · NCT07046585 · Data updated 2026-11-12
This will test whether Natera's blood-based colorectal cancer screening can find cancer in average-risk adults who are planning a colonoscopy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 25000 (estimated) |
| Sponsor | Natera, Inc. Industry-sponsored |
| Locations | 1 site (Austin, Texas) |
| Status | Recruiting |
| Started | May 30, 2025 |
| Main results expected | July 10, 2027 |
| Study ends | September 30, 2033 |
| Registry record updated | December 12, 2025 |
| Trial ID | NCT07046585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40 or older at average risk for colorectal cancer who are planning a standard-of-care colonoscopy and can provide a blood sample within 120 days of the procedure.
✕Probably not a fit
People under 40, those with a prior history of cancer, those having a diagnostic colonoscopy for symptoms, or those already up-to-date with non-invasive CRC screening are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
FIND-CRC is a prospective observational collection of blood samples and clinical data from average-risk adults who plan to undergo a standard-of-care colonoscopy. Participants provide a research blood draw within 120 days before their colonoscopy, and samples will be analyzed to determine how the Natera CRC Screening Test performs compared with colonoscopy findings. No blood test results are returned to participants or their clinicians, and enrollment excludes people with prior malignancies or recent/up-to-date CRC screening. The study is conducted by the sponsor at a single site in Austin, Texas.
Why it matters
Potential benefit: If successful, the blood test could offer a less invasive screening option that detects colorectal cancer earlier and may increase screening participation.
How similar studies have gone: Other blood-based and methylation-based CRC screening tests have shown some ability to detect colorectal cancer, but results vary and further validation in average-risk populations is still needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed informed consent. 2. 40 years of age or older at the time of consent. 3. Planning or intending to undergo a standard of care colonoscopy. 4. Able to tolerate venipuncture for research draw(s). 5. Able and willing to provide blood samples within the 120 days prior to a standard-of-care pre-bowel preparation procedure and colonoscopy procedure. 6. Willing and able to comply with the study visit schedule and study requirements. Exclusion Criteria: 1. Any prior history of any kind of malignancy (exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancers may be enrolled, provided the procedure was completed at least 12 months prior to consent for the study). 2. Had a complete colonoscopy with adequate bowel preparation in the previous nine (9) years. 3. Undergoing diagnostic colonoscopy for the investigation of symptoms. 4. Up to date with colorectal cancer screening from any non-invasive test. 5. Precancerous findings on most recent colonoscopy. 6. Had a prior colorectal resection for any reason other than sigmoid diverticular disease. 7. Known personal history of any of the following high-risk conditions: 7a. Inflammatory bowel disease. 7b. Known hereditary condition that would increase risk of colorectal cancer (example Lynch Syndrome).
Where it's running
-
Natera, Inc
Austin, Texas, United States Recruiting
Study contacts
- Study coordinator: FIND-CRC Study team
- Email: findcrc_ctgov@natera.com
- Phone: 650-489-9050
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prehabilitation before high-risk cancer surgery
This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.
-
Personal cancer risk testing using genetic, blood, and tumor monitoring
This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.
-
Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease
This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.
-
Colorectal Cancer Screening Outreach for Better Adherence
This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.
-
Blood-based delta-HLD methylation test for detecting colorectal cancer
This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.
-
MBRC-201 dose-finding and safety in advanced metastatic solid tumors
We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.